Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to ...

U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Eli Lilly says its GLP-1 drug in pill form is as safe and effective as Ozempic and other mega-popular injectable drugs for weight loss and lowering blood sugar. The company announ ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...